Investor Relations

 

Common Stock

Data as of

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Company Overview

We aspire to become a world leader in AI-immunology, decoding the human immune system to develop effective immunotherapies for cancer and infectious diseases based on deep biological insights. We believe our ground-breaking AI-immunology platforms PIONEER, EDEN and RAVEN, trained to simulate the immune system, can be harnessed to rapidly and cost effectively design and develop unique immunotherapies, thereby potentially revolutionizing the process of drug discovery and development. We have two patient-specific cancer immunotherapies in the clinic and are advancing a portfolio of vaccines to treat bacterial and viral infections. With an experienced management team, strong IP portfolio and scalable business model, Evaxion is well positioned for rapid growth.

Are you eager to deep-dive into Evaxion's business?
Download our latest presentation below, or click here to see all our latest presentations.

Latest News

Press Release

Jan 19, 2023

Evaxion receives FDA fast-track designation for personalized cancer immunotherapy

Press Release

Jan 03, 2023

Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01

Press Release

December 15, 2022

Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023

Press Release

Dec 6, 2022

Evaxion and ExpreS²ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate

Latest Quarterly Earnings

Q2

2022

Subscribe to Investor Email Alerts

Be the first to know about news, milestones and events at Evaxion by subscribing to our investor email alerts.